TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Robertson Dysarthria Profile
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Communication Effectiveness Measure
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Communicative Participation Item Bank
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Speech Intelligibility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: B
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity of autoantibody testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: specificity of autoantibody testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensitivity of bone marrow trephine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lower-limb amputee socket satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Frequency of Gene Alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in postural sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Pain Intensity Before and 30 Minute After Study Drug Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of cigarettes smoked per day (CPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fagerstrom Test for Nicotine Dependence (FTND) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical atherosclerosis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Hospital Charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Gut Microbiome Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Gut Metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in key Immune Populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 20 Week Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: One Year Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Two Year Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Hemoglobin change - reach of target Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weight Regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Malaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Global Wrinkling Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Striatal FEOVB PET Binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Striatal DTBZ PET Binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Striatal PIB PET Binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients requiring dose reduction or discontinuation due to chemotherapy-induced peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: maximum plasma olaparib concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration time curve from zero to the last measurable time point (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Early pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of early complications and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total insulin daily dose per kg per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Population pharmacokinetic parameters of Benznidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoogland score during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects without bleeding/spotting
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline ISR Erythema Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of transdermal formulations of fentanyl
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Rebound Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Serum Interleukin 6 (IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of IgE receptors and IgE binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change from Baseline of Plasma Low Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficiency of TVT and TOT in stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle contraction ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance in meters performed in the Incremental Shuttle Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-Free Survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Time to ready for discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of life including health status, behavior, and the subjective experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Freedom From Atrial Fibrillation, Atrial Tachycardia, or Atrial Flutter Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom From Serious Adverse Events Related to the Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functionality at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Dimensional Changes at Alveolar Ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic Dimensional Changes at Alveolar Ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Histology of the Bone Harvested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of bacterial pathogens in middle ear fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of Trephined Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of treatment regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microdevice-related failures or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of technical complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases with diagnostic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Function Scale (MFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in breast fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change in brain secretion of Dopamine at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in brain secretion of Noradrenaline at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in brain secretion of serotonin at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Area Under the Concentration-time Curve [AUC(0-tlast)] of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Concentration-time Curve [AUC(0-tlast)] of DRSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Groningen Activity Restriction Scale (GARS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in propofol clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative serum troponin I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration versus time curve of TRV130A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDI-2 Reduced Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Achievement of Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: adverse events (AE)'s
Endpoint domain: Adverse events/effects
Primary endpoint: serious adverse events (SAE)'s
Endpoint domain: Adverse events/effects
Primary endpoint: Effects of daily intake of Bif195
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Pregnancy Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Amblyopic Eye logMAR distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With ERCC1 Protein Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a completed advance directive
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average turnaround time for combined EGFR and ALK results reporting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Social functioning status
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: percentage error in discrimination test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Non Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Inpatient Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Numeric Rating Scale (NRS) Pain Score Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of biomarkers of abdominal organ injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE)
Endpoint domain: Adverse events/effects
Primary endpoint: Accepting Mental Illness Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual Refractive Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPEAK Survey (Baby Subscales)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: microbiota colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in glucose metabolism measured by fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in glucose metabolism measured by Homeostasis Model Assessment-index (HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in glucose metabolism measured by HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in subjective feeling of warmth at the feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative change of Observer's Assessment of Alertness/Sedation scale (OAA/S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference Score for the Log Value of K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive strain prevalence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy in predicting invasion depth of EGC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical ventilation dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of the DC bead TACE
Endpoint domain: Adverse events/effects
Primary endpoint: Peptic ulcer bleeding related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: urine opioid results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricle-end Systolic Volume (ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV-end Diastolic Volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Died Following Initiation of Index Treatment up to Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Ongoing Index Treatment at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Initiation of Next Treatment (TTNT) From Initiation of Palbociclib Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Height-for-weight Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery Success Rate for SMART across multiple tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Improvement in Tumor Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early failure of primary hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normalization of POC test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cessation of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients Without Any Need for INV Until EoS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of neuronal interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microbial composition of gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antioxidant activity oxygen radical absorption capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trolox equivalent antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain intensity on the days with pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Lequesne Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Percent of complete epithelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Level of follicle-stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of increase or stable donor chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Weight Loss From Baseline to Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients Alive at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Hepatic and systemic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Roentgen Stereophotogrammetric Analysis (RSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score (DAS28-4ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach normal body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of COVID-19 symptoms during HCQ preventive therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Development of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lencioni score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement Antibody (rSBA) Titers >=1:8 at 1 Month After Administration of 1 Dose of MenACWY-TT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With rSBA Titers >=1:8 at 1 Month After Administration of 2 Doses of MenACWY-TT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) of Antibodies for Each of the Anti-pneumococcal Serotypes at 1 Month After Administration of Prevnar 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of blood fibrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Forced Expiratory Volume (FEV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the ROC curve for sensitivity/specificity of glycosaminoglycan scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine output per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Persistence of Human Complement Serum Bactericidal Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Men With Confirmed Diagnosis of BPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI Intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in muscle layer thickness of the quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of maternal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement of perinatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Blood markers of liver cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of minimally invasive active surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Distance Transversed During the 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of American Shoulder and Elbow Surgeons (ASES) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline of Numeric Pain Rating Scale (NPRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue